ARCHIVES

Richard Klausner resigned from the Gates Foundation, saying move was unrelated to Congressional investigation of NCI contract to Harvard University during Klausner’s tenure as NCI director.

This article is from The Cancer Letter archive.

Vol. 31 No. 33 | September 16, 2005

Download PDF Visit The Full Archive

Related Articles

FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.

January 14, 2005

In Brief: NCAB To Hear NCOG Appeal; FDA Renege On New Toxicology Protocol, Holds Up INDs

April 24, 1981

Merritt To Head Nursing Center’s Implementation; Nurse Research And Training Opportunities Varied

January 10, 1986

FDA Discloses Avastin Regulatory History.

December 14, 2007

LabCorp Marketing Of Ovarian Cancer Test Unlawful, FDA Says In Warning Letter.

October 17, 2008

In Brief: DeVita Says He’ll Go Along With Any NCAB Decision On Organ Site Program; Talbt New AACI President

February 26, 1982